Drugs / SSGJ-707
Trials 5
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 24 trials | ||||||
| Phase 2 | NCT06522828 | Oct 2024 → Aug 2025 overdue | reproductive system cancer | Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd. | Recruiting | No outcome recorded |
| Phase 2 | NCT06493760 | Sep 2024 → Jun 2025 overdue | colorectal cancer | Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd. | Recruiting | No outcome recorded |
| Phase 2 | NCT06412471 | Jul 2024 → Jul 2025 | — | Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd. | Unknown | No outcome recorded |
| Phase 2 | NCT06361927 | May 2024 → Jun 2025 | non-small cell lung carcinoma | Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd. | Unknown | No outcome recorded |
| Phase 31 trial | ||||||
| Phase 3 | NCT06980272 | Jun 2025 → Jul 2026 overdue | non-small cell lung carcinoma | Shenyang Sunshine Pharmaceutical Co., LTD. | Recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 5 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | SSGJ-707 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06522828 ↗ |
| Route | Intravenous | “Subjects receive SSGJ-707 intravenously.” NCT06980272 ↗ |